3/29/2013 10:45:14 AM
Astellas Pharma, Inc. and Zeria Pharmaceutical Co., Ltd. recently announced that it received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Acofide for the treatment of functional dyspepsia (FD). The regulatory application was based on a multicenter, randomized, double-blind, parallel-group and placebo-controlled phase III clinical study. The results showed statistically significant data when compared to placebo, in both the primary endpoints and several secondary endpoints.
comments powered by